Gabriela Chiritoiu, PhD

Gabriela Chiritoiu
Group: Molecular Cell Biology
Department: Molecular Cell Biology

Scientific Researcher III

Biography

Gabriela Chiritoiu graduated from Faculty of Chemistry, University of Bucharest (2004-2008). She received her Ph.D. in Biology from the Institute of Biochemistry of the Romanian Academy in 2016, under the supervision of dr. Stefana Petrescu and her thesis was focused on investigating the role of glycosylation and ERAD (endoplasmic reticulum associated degradation) in epitope generation and antigen presentation.

Papers

Year
  • Anghel SA, Badea RA, Chiritoiu G, Patriche DS, Alexandru PR, Pena FAnghel SA et al . "Novel luciferase-based GLP-1 reporter assay reveals naturally-occurring secretagogues", British journal of pharmacology, (2022)
    IF: 9.47AI: 1.62
  • Iulia-Roxana Angelescu, Silvia-Simona Grosu-Tudor # 1, Lucia-Roxana Cojoc, Gabriel-Mihai Maria, Gabriela N Chirițoiu, Cristian V A Munteanu, Medana ZamfirIulia-Roxana Angelescu et al . "Isolation, characterization, and mode of action of a class III bacteriocin produced by Lactobacillus helveticus 34.9", World J Microbiol Biotechnol .(38): 220, (2022)
    IF: 4.25AI: 0.64
  • Marioara Chiritoiu-Butnaru, Gabriela Chiritoiu, Simona Ghenea, Gheorghița IsvoranuMarioara Chiritoiu-Butnaru et al . "Linie celulara reporter pentru testarea activitatii unor modulatori ai sintezei si secretiei proteinei IL-1B", OSIM, (2022)
  • Munteanu CVA, Chirițoiu GN, Chirițoiu M, Ghenea S, Petrescu AJ, Petrescu ȘMMunteanu CVA et al . "Affinity proteomics and deglycoproteomics uncover novel EDEM2 endogenous substrates and an integrative ERAD network", Molecular & cellular proteomics : MCP: 100125, (2021)
    IF: 5.91AI: 2.26
  • Manica G, Ghenea S, Munteanu CVA, Martin EC, Butnaru C, Surleac M, Chiritoiu GN, Alexandru PR, Petrescu AJ, Petrescu SMManica G et al . "EDEM3 Domains Cooperate to Perform Its Overall Cell Functioning", Int. J. Mol. Sci. 4(22): 2172, (2021)
    IF: 4.56
  • Chirițoiu GN, Chirițoiu M, Munteanu CVAChirițoiu GN et al . "Dataset of human EDEM2 melanoma cells proteomics, affinity proteomics and deglycoproteomics", Data in brief 39: 107471, (2021)
  • Chiritoiu M, Chiritoiu GN, Munteanu CVA, Pastrama F, Ivessa NE and Petrescu SMChiritoiu M et al . "EDEM1 Drives Misfolded Protein Degradation via ERAD and Exploits ER-Phagy as Back-Up Mechanism When ERAD Is Impaired", International Journal of Molecular Sciences 10(21): 3468, (2020)
    IF: 4.10
  • Gheorghe RO, Deftu A, Filippi A, Grosu A, Bica-Popi M, Chiritoiu M, Chiritoiu G, Munteanu C, Silvestro L, Ristoiu VGheorghe RO et al . "Silencing the Cytoskeleton Protein Iba1 (Ionized Calcium Binding Adapter Protein 1) Interferes with BV2 Microglia Functioning", Cellular and molecular neurobiology, (2020)
    IF: 3.80
  • Sima LE, Chiritoiu G, Negut I, Grumezescu V, Orobeti S, Munteanu CVA, Sima F, Axente ESima LE et al . "Functionalized Graphene Oxide Thin Films for Anti-tumor Drug Delivery to Melanoma Cells", Frontiers in chemistry 8: 184, (2020)
    IF: 3.70
  • Mernea M, Ulăreanu R, Călboreanu O, Chirițoiu G, Cucu D, Mihăilescu DFMernea M et al . "N-glycosylation state of TRPM8 protein revealed by terahertz spectroscopy and molecular modelling", Biochimica et biophysica acta. General subjects 1864(7): 129580, (2020)
    IF: 3.42
  • Coman AG, Paun A, Popescu CC, Hădade ND, Hanganu A, Chiritoiu G, Farcasanu IC, Matache MComan AG et al . "A novel adaptive fluorescent probe for cell labelling", Bioorg Chem.(92): 103295, (2019)
    IF: 3.93
  • Munteanu CVA, Chiritoiu GN, Petrescu AJ, Petrescu ȘMMunteanu CVA et al . "Profiling Optimal Conditions for Capturing EDEM Proteins Complexes in Melanoma Using Mass Spectrometry", Advances in experimental medicine and biology 1140: 155-167, (2019)
    IF: 2.13
  • Butnaru CM, Chiritoiu MB, Chiritoiu GN, Petrescu SM, Petrescu AJButnaru CM et al . "Inhibition of N-glycan processing modulates the network of EDEM3 interactors", Biochemical and biophysical research communications 486(4): 978-984, (2017)
    IF: 2.56
  • Ulăreanu R, Chiriţoiu G, Cojocaru F, Deftu A, Ristoiu V, Stănică L, Mihăilescu DF, Cucu DUlăreanu R et al . "N-glycosylation of the transient receptor potential melastatin 8 channel is altered in pancreatic cancer cells", Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 39(8): 1010428317720940, (2017)
  • Grumezescu V, Holban AM, Sima LE, Chiritoiu MB, Chiritoiu GN, Grumezescu AM, Ivan L, Safciuc F, Antohe F, Florica C, Luculescu CR, Chifiriuc MC, Socol GGrumezescu V et al . "Laser deposition of poly(3-hydroxybutyric acid-co-3-hydroxyvaleric acid) - lysozyme microspheres based coatings with anti-microbial properties", International journal of pharmaceutics 521(1-2): 184-195, (2017)
  • Chiritoiu GN, Jandus C, Munteanu CV, Ghenea S, Gannon PO, Romero P, Petrescu SMChiritoiu GN et al . "Epitope located N-glycans impair the MHC-I epitope generation and presentation", Electrophoresis 37(11): 1448-60, (2016)
    IF: 2.74
  • GABRIELA N. CHIRIȚOIU, CRISTIAN V.A. MUNTEANU, NICULINA MITREAGABRIELA N. CHIRIȚOIU et al . "COMBINING HETEROLOGOUS BACTERIAL EXPRESSION SYSTEM WITH AFFINITY CHROMATOGRAPHY PURIFICATION TO OBTAIN NATIVE MOUSE TYROSINASE", Farmacia 2(63): 254-261, (2015)
    IF: 1.16
  • Cucu D, Chiritoiu G, Petrescu S, Babes A, Stanica L, Duda DG, Horii A, Dima SO, Popescu ICucu D et al . "Characterization of functional transient receptor potential melastatin 8 channels in human pancreatic ductal adenocarcinoma cells", Pancreas 43(5): 795-800, (2014)
    IF: 2.96AI: 0.90
  • Marin MB, Ghenea S, Spiridon LN, Chiritoiu GN, Petrescu AJ, Petrescu SMMarin MB et al . "Tyrosinase degradation is prevented when EDEM1 lacks the intrinsically disordered region", PloS one 7(8): e42998, (2012)
View all papers

Grants

Microfluidic assay of FGF2 therapeutic administration for bone regeneration 2017-2019
Acronym: μFGF2bone
Project director: Gabriela Chiritoiu

Musculoskeletal disorders affect 1 in 7 people and fractures alone affect 1 in 50 people annually while 10% of bone injuries fail to heal. Our present proposal aims to test for the first time the potential of fibroblast growth factor-2 (FGF2), to be administered as a stimulatory drug to enhance bone regeneration.

Role of TG2 in cancer tumor microenvironment for guiding metastasis prevention therapeutic approaches 2020-2022
Acronym: TG2TARGET
Budget: 431,900 RON
Project director: Livia Sima

The overall goal of the current project is to understand the impact of tissue transglutaminase (TG2) targeting in the context of ovarian cancer (OC) tumor microenvironment (TME). Our aproach is aimed at testing the hypothesis that interventions in targeting TG2 in the OC TME will disrupt pro-tumorigenic signaling cross-talk within tumors.

Context-dependent therapeutic targeting of ovarian cancer metastasis using TG2 small molecule inhibitors 2020-2022
Acronym: TG2THERAPY
Budget: 600,000 RON
Project director: Livia Sima

The principal goal of this project is the development of a new class of small molecule inhibitors (SMIs) targeting TG2-FN interaction, which is currently in the phase of lead optimization, translatable to clinical use for prevention of ovarian cancer dissemination, either alone or in combinations.

Identification of new molecules involved in melanoma associated antigens production 2020-2022
Acronym: ImmunoMOD
Budget: 246,950 RON
Project director: Gabriela Chiritoiu

This project aims to develop new strategies to improve the capacity of antigen presenting tumor cells to activate cytotoxic T cells and hamper immune escape mechanisms in cancer.